Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 8/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | PGR | P06401 | 4/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.70 |
| ▸ | AR | P10275 | 2/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | TNF | P01375 | 1/20 | 0.70 |
| ▸ | IL6 | P05231 | 1/20 | 0.70 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.70 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.70 |
| ▸ | GLUL | P15104 | 1/20 | 0.70 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.70 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7142738 | 0.99 | HIF1A (0.79) | HIF1ALMNAPGRSMN1; SMN2POLB | |
| SCHEMBL7145316 | 0.99 | HIF1A (0.79) | HIF1ALMNAPGRSMN1; SMN2POLB | |
| SCHEMBL7613021 | 0.99 | HIF1A (0.79) | HIF1ALMNAPGRSMN1; SMN2POLB | |
| SCHEMBL11090884 | 0.99 | HIF1A (0.79) | HIF1ALMNAPGRSMN1; SMN2POLB | |
| SCHEMBL10363483 | 0.98 | HIF1A (0.82) | HIF1ALMNAPGRSMN1; SMN2POLB | |
| SCHEMBL677625 | 0.98 | HIF1A (0.82) | HIF1ALMNAPGRSMN1; SMN2POLB | |
| Prednisolone Steaglate SCHEMBL136864 | 0.98 | HIF1A (0.77) | HIF1ALMNAPGRSMN1; SMN2POLB | |
| Prednisolone Acetate SCHEMBL9838659 | 0.95 | HIF1A (0.86) | HIF1ALMNAPGRSMN1; SMN2POLB | |
| SCHEMBL16018292 | 0.95 | HIF1A (0.85) | HIF1ALMNAPGRSMN1; SMN2POLB | |
| SCHEMBL6715060 | 0.95 | HIF1A (0.73) | HIF1ALMNAPGRSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 538 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4580674-A2 | ANTIGEN BINDING MOLECULES TARGETING PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) | Flagship Pioneering Innovations VI, LLC (US) | 2025-07-09 | — | — | EP | claimed |
| WO-2024050421-A2 | ANTIGEN BINDING MOLECULES TARGETING PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2024-03-07 | — | — | WO | claimed |
| CN-112584874-A | Compositions and methods for treating leber's hereditary optic neuropathy | 武汉纽福斯生物科技有限公司 | 2021-03-30 | — | — | CN | claimed |
| CN-1447804-A | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS INC (US) | 2003-10-08 | — | — | CN | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | NIPPON CHEMIPHAR CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-04-14 | — | — | US | disclosed |
| US-20260083735-A1 | ABHD6 ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-03-26 | — | — | US | disclosed |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TAKASAKI UNIV OF HEALTH AND WELFARE (JP) | 2026-01-01 | — | — | US | disclosed |
| US-20250368736-A1 | BISPECIFIC ANTIBODY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-12-04 | — | — | US | disclosed |
| EP-4596555-A1 | ABHD6 ANTAGONIST | ONO Pharmaceutical Co., Ltd. (JP) | 2025-08-06 | — | — | EP | disclosed |
| EP-4580674-A2 | ANTIGEN BINDING MOLECULES TARGETING PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) | Flagship Pioneering Innovations VI, LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-6248779-B1 | SYNERGISTIC MIXTURE OF VITAMIN E AND SQUALANE | SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2001-06-19 | — | — | US | disclosed |
| EP-0665009-B1 | CRYSTALLINE CONDITION DISLOCATING METHOD | NIPPON SHINYAKU CO LTD (JP) | 2000-02-16 | — | — | EP | disclosed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| EP-0766960-A1 | EXTERNAL PREPARATIONS FOR TREATING DERMATOSES | SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1997-04-09 | — | — | EP | disclosed |
| EP-0575841-B1 | Composition containing dibucaine hydrochloride, a salicylate, calcium bromide and an antiphlopstic steroid for the treatment of pain | VITACAIN PHARMACEUTICAL CO LTD (JP) | 1996-08-28 | — | — | EP | disclosed |
| EP-0665009-A1 | CRYSTALLINE CONDITION DISLOCATING METHOD | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-08-02 | — | — | EP | disclosed |
| EP-0575841-A1 | Composition containing dibucaine hydrochloride, a salicylate, calcium bromide and an antiphlopstic steroid for the treatment of pain | VITACAIN PHARMACEUTICAL CO., Ltd. (JP) | 1993-12-29 | — | — | EP | disclosed |
| US-5260289-A | Vitacain\" (dibucaine, sodium salicylate, calcium bromide) and antiphlogistic steroid | VITACAIN PHARMACEUTICAL CO., LTD. | 1993-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | HRH2, HRH4, HRH1 | HIF1A 1693/4885LMNA 1833/4885PGR 322/4885 |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TRPV1, TRPV4, TRPV5 | HIF1A 1324/4885LMNA 3760/4885PGR 1686/4885 |
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ABHD6, ABHD16A, HDHD5 | HIF1A 2641/4885LMNA 3288/4885PGR 4677/4885 |
| US-20260083735-A1 | ABHD6 ANTAGONIST | ABHD6, ABHD16A, ABHD12 | HIF1A 3390/4885LMNA 3657/4885PGR 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.